Evidence map›Paper›PMID 32615986›Full record

ArticleRetrovirology2020

Increased expression of CDKN1A/p21 in HIV-1 controllers is correlated with upregulation of ZC3H12A/MCPIP1.

Suwellen S D de Azevedo, Marcelo Ribeiro-Alves, Fernanda H Côrtes, Edson Delatorre, Lucia Spangenberg, Hugo Naya, Leonardo N Seito, Brenda Hoagland, Beatriz Grinsztejn, Valdilea G Veloso and 3 more

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Suwellen S D de AzevedoLaboratório de AIDS & Imunologia Molecular, Instituto Oswaldo Cruz-IOC, FIOCRUZ, Av. Brasil 4365, Rio de Janeiro, RJ, 21045-900, Brazil. suwellen@ioc.fiocruz.br.ORCID 0000-0001-6681-0987
Marcelo Ribeiro-AlvesLaboratório de Pesquisa Clínica em DST-AIDS, Instituto Nacional de Infectologia Evandro Chagas-INI, FIOCRUZ, Rio de Janeiro, Brazil.
Fernanda H CôrtesLaboratório de AIDS & Imunologia Molecular, Instituto Oswaldo Cruz-IOC, FIOCRUZ, Av. Brasil 4365, Rio de Janeiro, RJ, 21045-900, Brazil.
Edson DelatorreDepartamento de Biologia, Centro de Ciências Exatas, Naturais e da Saúde, Universidade Federal do Espírito Santo, Alegre, Brazil.
Lucia SpangenbergUnidad de Bioinformática, Institut Pasteur Montevideo, Montevideo, Uruguay.
Hugo NayaUnidad de Bioinformática, Institut Pasteur Montevideo, Montevideo, Uruguay.
Leonardo N SeitoLaboratório de Farmacologia Aplicada, Instituto de Tecnologia em Fármacos-Farmanguinhos FIOCRUZ, Rio de Janeiro, Brazil.
Brenda HoaglandLaboratório de Pesquisa Clínica em DST-AIDS, Instituto Nacional de Infectologia Evandro Chagas-INI, FIOCRUZ, Rio de Janeiro, Brazil.
Beatriz GrinsztejnLaboratório de Pesquisa Clínica em DST-AIDS, Instituto Nacional de Infectologia Evandro Chagas-INI, FIOCRUZ, Rio de Janeiro, Brazil.
Valdilea G VelosoLaboratório de Pesquisa Clínica em DST-AIDS, Instituto Nacional de Infectologia Evandro Chagas-INI, FIOCRUZ, Rio de Janeiro, Brazil.
Mariza G MorgadoLaboratório de AIDS & Imunologia Molecular, Instituto Oswaldo Cruz-IOC, FIOCRUZ, Av. Brasil 4365, Rio de Janeiro, RJ, 21045-900, Brazil.
Thiago Moreno L SouzaNational Institute for Science and Technology on Innovation on Diseases of Neglected Populations (INCT/IDPN), FIOCRUZ, Center for Technological Development in Health-CDTS, Rio de Janeiro, Brazil.
Gonzalo BelloLaboratório de AIDS & Imunologia Molecular, Instituto Oswaldo Cruz-IOC, FIOCRUZ, Av. Brasil 4365, Rio de Janeiro, RJ, 21045-900, Brazil.
Fundação Oswaldo Cruz · BRInstituto Evandro Chagas · BRUniversidad de la República de Uruguay · UYFarmacore (Brazil) · BRUniversidade Federal do Espírito Santo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSome multifunctional cellular proteins, as the monocyte chemotactic protein-induced protein 1 (ZC3H12A/MCPIP1) and the cyclin-dependent kinase inhibitor CDKN1A/p21, are able to modulate the cellular susceptibility to the human immunodeficiency virus type 1 (HIV-1). Several studies showed that CDKN1A/p21 is expressed at high levels ex vivo in cells from individuals who naturally control HIV-1 replication (HIC) and a recent study supports a coordinate regulation of ZC3H12A/MCPIP1 and CDKN1A/p21 transcripts in a model of renal carcinoma cells. Here, we explored the potential associations between mRNA expression of ZC3H12A/MCPIP1 and CDKN1A/p21 in HIC sustaining undetectable (elite controllers-EC) or low (viremic controllers-VC) viral loads.

resultsWe found a selective upregulation of ZC3H12A/MCPIP1 and CDKN1A/p21 mRNA levels in PBMC from HIC compared with both ART-suppressed and HIV-negative control groups (P≤ 0.02) and higher MCPIP1 and p21 proteins levels in HIC than in HIV-1 negative subjects. There was a moderate positive correlation (r ≥ 0.57; P ≤ 0.014) between expressions of both transcripts in HIC and in HIC combined with control groups. We found positive correlations between the mRNA level of CDKN1A/p21 with activated CD4

conclusionsThese data show for the first time the simultaneous upregulation of ZC3H12A/MCPIP1 and CDKN1A/p21 transcripts in the setting of natural suppression of HIV-1 replication in vivo and the positive correlation of the expression of these cellular factors in disparate cohorts of HIV-positive individuals. The existence of a common regulatory pathway connecting ZC3H12A/MCPIP1 and CDKN1A/p21 could have a synergistic effect on HIV-1 replication control and pharmacological manipulation of these multifunctional host factors may open novel therapeutic perspectives to prevent HIV-1 replication and disease progression.

Indexed as

CD4-Positive T-LymphocytesCyclin-Dependent Kinase Inhibitor p21FemaleHIV-1HIV InfectionsHumansLeukocytes, MononuclearMonocytesRibonucleasesRNA, MessengerTranscription FactorsUp-RegulationViral LoadCDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21RibonucleasesRNA, MessengerTranscription FactorsZC3H12A protein, humanHIV-1 controllersImmune activationMCPIP1p21Restriction factors

Identifiers

PMID32615986
PMCPMC7333275
OpenAlexW3039401440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.